Technology

An integrated in vivo CAR-T platform engineered to target and reprogramme solid tumours.

Cancer

10 million people die from cancer each year- with solid tumours remaining the greatest challenge

HypoxiCAR

Our in vivo CAR-T platform designed to detect, activate and eradicate cancer

KOR101

Our lead therapy, engineered to overcome heterogeneity and immune suppression, unlocking lasting tumour elimination

Training the immune system to take on solid tumours

The immune system has a remarkable ability to recognise and destroy abnormal cells while sparing healthy tissue. Cancer cells, however, evolve sophisticated ways to hide, evade detection, and spread uncontrollably.

At Korecyte Bio, we are a Pre-Seed-funded company on a mission to rewrite the rules of CAR-T therapy. Traditional CAR-T relies on extracting and engineering a patient’s T-cells in the laboratory before reinfusion-a process that is complex, costly, and difficult to scale. Standard CAR approaches are also not designed to overcome the hostile tumour microenvironment, which drives immune suppression, heterogeneity, and cancer escape. Any one of these hurdles can prevent CAR-T from delivering cures in solid tumours.

We have reimagined this approach with a fully in vivo CAR-T strategy that generates tumour-fighting immune cells directly inside the patient, delivering precision, potency, and scalability like never before. With KOR101, cancers have nowhere left to hide.

When CAR-T cells find cancerous cells, the CAR engineered onto the T-cell surface sends a signalling into the T-cell to trigger their innate ability to kill the target cancer cell. These therapies have revolutionised the treatment of certain liquid cancers. However, their use against solid tumours has highlighted barriers for these types of cancer.

We at Korecyte Bio are re-thinking CAR-T for the treatment of solid tumours to break down current barriers for improved outcome for patients with cancer. The HypoxiCAR technology is currently at the preclinical stage.

Korecyte Bio is an international biotech startup based between the Netherlands and United Kingdom that was established in 2023. Our mission is to develop next-generation CAR-T cellular immunotherapies

KOR101: A disruptive, pan-cancer in vivo CAR-T therapy

KOR101 is our lead therapy, engineered to tackle heterogeneity and immune suppression-two of the greatest challenges in solid tumours. By combining broadly targeting CARs with potent payloads under the control of the superior precision of HYpoxiCAR it is able to selectively reprogramme the tumour microenvironment. KOR101 equips the immune system to detect, rewire the microenvironment and destroy cancer cells across multiple solid tumour types. One therapy, multiple cancers.

Because KOR101 operates entirely in vivo, it is readily scalable, offering a path to reach patients at lower cost and with broader impact than traditional CAR-T approaches. This all-in-one therapy is designed not only to kill cancer cells, but to unlock durable anti-tumour immunity, rewriting what CAR-T can achieve against solid cancers.

Why Korecyte Bio is different

Korecyte Bio is not just improving CAR-T therapy-we are redefining it. By combining pan-cancer targeting, immune microenvironment rewiring, and in vivo generation, our approach creates a scalable, versatile, all-in-one solution for the most challenging solid cancers.

Pan-cancer targeting: Our CARs recognise antigens shared across multiple solid tumours, making escape difficult.
TME modulation: KOR101 delivers potent payloads that reprogramme the tumour microenvironment, overcoming immune suppression.
In vivo scalability: By generating CAR-T cells directly inside the patient, we simplify manufacturing and increase accessibility worldwide.
Integrated potency and safety: Our therapies activate precisely within tumours, maximising anti-cancer effects while minimising off-target toxicity.

We are rigorous in our pursuit of KOR101, aiming to deliver a therapy that is powerful, precise, and accessible-a single, integrated in vivo CAR-T platform capable of tackling cancer at its core.

Our academic paper for the technology was selected as one of the top 10 most influential articles of the year at Cell Reports Medicine (IF18) (download):
Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors